| Abstrakt: |
While many previous studies on the localization and function of tissue or local RAS have focused on their pathophysiological relevance, many new aspects of the physiological role of these systems are still undiscovered. The previous clinical extensive research of angiotensin converting enzyme inhibitors (ACEi) and angiotensin AT1 receptor antagonists (ARBs) as antihypertensive agents provided a numerous examples of enigmatic experiences in improving of hypertension at diabetic nephropathy (DN). This research aims to determine the impact of ACEi, Perindopril and ARBs AT1, Candesartan, singly and in combination on the level of serotonin in the serum at Wistar rats with diabetic nephropathy induced with Streptozotocin (STZ). The Serotonin levels in the serum were measured with enzyme-linked immunosorbent assay (ELISA), on four experimental groups: control group with DN, group with DN + Perindopril, group with DN + Candesartan and the DN group in combination with Perindopril + Candesartan. Perindopril (6 mg/Kg/day), Candesartan (5mg/Kg/day) and dual therapy with Perindopril (3mg/Kg/day) and Candesartan (2,5mg/Kg/day) was administered peroraly every day during 8 weeks, starting after 4 weeks from administration of STZ, while the control group received water alone. At the end of treatment the rats were sacrificed so the serum was taken for the measurement of Serotonin levels. The results demonstrate that in all groups, the blockade of renin – angiotensin system (RAS), with Perindopril, Candesartan and their combination significantly decrease the level of Serotonin in the serum. [ABSTRACT FROM AUTHOR] |
